David Valcárcel

6.7k total citations
157 papers, 2.9k citations indexed

About

David Valcárcel is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, David Valcárcel has authored 157 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Hematology, 48 papers in Genetics and 34 papers in Immunology. Recurrent topics in David Valcárcel's work include Hematopoietic Stem Cell Transplantation (64 papers), Acute Myeloid Leukemia Research (63 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers). David Valcárcel is often cited by papers focused on Hematopoietic Stem Cell Transplantation (64 papers), Acute Myeloid Leukemia Research (63 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (24 papers). David Valcárcel collaborates with scholars based in Spain, United States and Italy. David Valcárcel's co-authors include Rodrigo Martino, Jorge Sierra, Salut Brunet, José Luís Piñana, Pere Barba, Josè Antonio Pérez-Simón, Anna Sureda, Javier Briones, Julio Delgado and Carmen Martı́nez and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

David Valcárcel

144 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Valcárcel Spain	32	2.0k	765	700	578	439	157	2.9k
Hiroyasu Ogawa Japan	33	1.8k 0.9×	442 0.6×	882 1.3×	735 1.3×	535 1.2×	153	3.0k
Taner Demirer Türkiye	31	2.2k 1.1×	512 0.7×	1.2k 1.7×	763 1.3×	338 0.8×	101	3.2k
Peter Kalhs Austria	34	2.4k 1.2×	478 0.6×	573 0.8×	1.1k 1.8×	325 0.7×	119	3.3k
Anne Huynh France	28	1.6k 0.8×	499 0.7×	593 0.8×	359 0.6×	625 1.4×	130	2.7k
Cynthia L. Toze Canada	26	1.3k 0.6×	685 0.9×	614 0.9×	388 0.7×	192 0.4×	72	2.1k
Sergio Giralt United States	21	3.0k 1.5×	601 0.8×	799 1.1×	719 1.2×	338 0.8×	40	3.6k
Michele Falda Italy	25	1.8k 0.9×	885 1.2×	551 0.8×	660 1.1×	1.3k 2.9×	55	3.6k
Betül Oran United States	30	2.3k 1.2×	558 0.7×	606 0.9×	464 0.8×	623 1.4×	173	2.9k
Daniel Lysák Czechia	18	1.1k 0.5×	671 0.9×	407 0.6×	332 0.6×	585 1.3×	83	1.9k
Görgün Akpek United States	25	1.1k 0.6×	399 0.5×	465 0.7×	385 0.7×	403 0.9×	65	2.0k

Countries citing papers authored by David Valcárcel

Since Specialization

Citations

This map shows the geographic impact of David Valcárcel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Valcárcel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Valcárcel more than expected).

Fields of papers citing papers by David Valcárcel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Valcárcel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Valcárcel. The network helps show where David Valcárcel may publish in the future.

Co-authorship network of co-authors of David Valcárcel

This figure shows the co-authorship network connecting the top 25 collaborators of David Valcárcel. A scholar is included among the top collaborators of David Valcárcel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Valcárcel. David Valcárcel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Campillo‐Marcos, Ignacio, Verónica Dávalos, Gerardo Ferrer, et al.. (2024). Single-cell Multiomics Analysis of Myelodysplastic Syndromes and Clinical Response to Hypomethylating Therapy. Cancer Research Communications. 4(2). 365–377. 6 indexed citations

Pascual, Cristina, et al.. (2024). Immune thrombotic thrombocytopenic purpura: clinical suspicion and basic management in emergency departments — an expert review and consensus statement from the Spanish societies of hematology and hemotherapy (SEHH) and emergency medicine (SEMES). Emergencias. 35(1). 44–52.

Zeidan, Amer M., Uwe Platzbecker, Matteo Giovanni Della Porta, et al.. (2024). Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.. Journal of Clinical Oncology. 42(16_suppl). 6565–6565. 2 indexed citations

Campillo‐Marcos, Ignacio, Verónica Dávalos, Carlos A. García‐Prieto, et al.. (2024). DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study. British Journal of Haematology. 204(5). 1838–1843. 1 indexed citations

Garcia‐Manero, Guillermo, Matteo Giovanni Della Porta, Valeria Santini, et al.. (2024). Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia. 24. S192–S192. 1 indexed citations

Garcia‐Manero, Guillermo, Uwe Platzbecker, Valeria Santini, et al.. (2023). Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).. Journal of Clinical Oncology. 41(16_suppl). 7003–7003.

Szabolcs, Paul, Roei David Mazor, Dima Yackoubov, et al.. (2023). Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy. Transplantation and Cellular Therapy. 29(8). 517.e1–517.e12. 6 indexed citations

Cooper, Nichola, Waleed Ghanima, Nicola Vianelli, et al.. (2023). Sustained response off‐treatment in eltrombopag‐treated adult patients with ITP who are refractory or relapsed after first‐line steroids: Primary, final, and ad‐hoc analyses of the Phase II TAPER trial. American Journal of Hematology. 99(1). 57–67. 11 indexed citations

Horwitz, Mitchell E., Patrick J. Stiff, Corey Cutler, et al.. (2022). Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplant with Omidubicel Demonstrates Sustained Clinical Improvement Versus Standard Myeloablative Umbilical Cord Blood Transplantation (UCBT): Final Results of a Phase III Randomized, Multicenter Study. Transplantation and Cellular Therapy. 28(3). S73–S74. 1 indexed citations

10.

Lozano, Marı́a Luisa, Mireia Coma, María Román, et al.. (2021). Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. International Journal of Molecular Sciences. 22(13). 6907–6907. 15 indexed citations

11.

Koning, Coco de, Weiyang Tao, Mitchell E. Horwitz, et al.. (2021). Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplantation. 56(11). 2826–2833. 3 indexed citations

12.

Jiménez, Moraima, Sabela Bobillo, Alba Cabirta, et al.. (2020). Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Blood. 136(Supplement 1). 14–16. 2 indexed citations

13.

Fox, María Laura, Irene García‐Cadenas, Ariadna Pérez, et al.. (2020). Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. Leukemia & lymphoma. 61(8). 1823–1832. 2 indexed citations

14.

Carrillo‐Cruz, Estrella, José R. García‐Lozano, Francisco J. Márquez‐Malaver, et al.. (2019). Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms. Clinical Cancer Research. 25(15). 4616–4623. 7 indexed citations

15.

Santini, Valeria, David Valcárcel, Uwe Platzbecker, et al.. (2019). Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research. 25(23). 6976–6985. 60 indexed citations

16.

Mingot‐Castellano, María Eva, María Román, Tomás José González‐López, et al.. (2019). Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group. Advances in Hematology. 2019. 1–11. 5 indexed citations

17.

Ortí, Guillermo, Jaime Sanz, Irene García‐Cadenas, et al.. (2018). Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions. Experimental Hematology. 62. 24–32. 9 indexed citations

18.

Caballero‐Velázquez, Teresa, Isabel Montero, Fermín Sánchez‐Guijo, et al.. (2016). Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clinical Cancer Research. 22(23). 5673–5681. 36 indexed citations

19.

García‐Cadenas, Irene, Cristina Díaz de Heredia, Rodrigo Martino, et al.. (2016). Cord Blood Units with High CD3+ Cell Counts Predict Early Lymphocyte Recovery After In Vivo T Cell–Depleted Single Cord Blood Transplantation. Biology of Blood and Marrow Transplantation. 22(6). 1073–1079. 11 indexed citations

20.

Barba, Pere, Rodrigo Martino, Josè Antonio Pérez-Simón, et al.. (2013). Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 20(1). 66–72. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact